Roman Sinichkin / Shutterstock.com
Pharmaceutical pay-for-delay deals worth less than around $10 million are unlikely to be challenged by the authorities in US courts, according to a speaker at the 2016 AIPPI World Congress in Milan.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AIPPI; AIPPI 2016; pay-for-delay deals; patent; generic drugs; pharmaceuticals